Yumanity Therapeutics, Inc. – NASDAQ:YMTX

Yumanity Therapeutics stock price today

$1.89
+0.14
+8.62%
Financial Health
0
1
2
3
4
5
6
7
8
9

Yumanity Therapeutics stock price monthly change

-4.40%
month

Yumanity Therapeutics stock price quarterly change

-0.57%
quarter

Yumanity Therapeutics stock price yearly change

-43.69%
year

Yumanity Therapeutics key metrics

Market Cap
 15.72M
Enterprise value
 N/A
P/E
 -0.44
EV/Sales
 -1.09
EV/EBITDA
 0.17
Price/Sales
 0.60
Price/Book
 0.53
PEG ratio
 -0.01
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 -660.61%
Oper. margin
 -643.37%
Gross margin
 49.94%
EBIT margin
 -643.37%
EBITDA margin
 N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Yumanity Therapeutics stock price history

Yumanity Therapeutics stock forecast

Yumanity Therapeutics financial statements

Quarterly Earnings

Yumanity Therapeutics, Inc. (NASDAQ:YMTX): Earnings per share (EPS)
2022-05-12 -6.65 -6.16
YMTX earnings history

Yumanity Therapeutics alternative data

Yumanity Therapeutics
Employees

Yumanity Therapeutics, Inc. (NASDAQ:YMTX): Employee count
Aug 2023 40
Sep 2023 40
Oct 2023 40
Nov 2023 40
Dec 2023 40
Jan 2024 40
Feb 2024 40
Mar 2024 40
Apr 2024 40
May 2024 40
Jun 2024 40
Jul 2024 40
Dec 2024 40

Yumanity Therapeutics other data

Yumanity Therapeutics
Insider Trading

Yumanity Therapeutics, Inc. (NASDAQ:YMTX): Insider trades (number of shares)
Period Buy Sel
Feb 2022 0 1958
Mar 2022 0 10715
Jun 2022 0 17822
Jul 2022 0 4584
Dec 2022 0 19098
Transaction Date Insider Security Shares Price per share Total value Source
Sale
SMITH DEVIN WHITTEMORE officer: SVP and General Counsel
 Common Stock 3,116 $1.69 $5,269
Sale
EPSTEIN MARIE officer: Principal Accounting O..
 Common Stock 1,976 $1.69 $3,341
Sale
WYZGA MICHAEL D officer: Sr. VP & Chief Financi..
 Common Stock 3,116 $1.69 $5,269
Sale
PETERS RICHARD director, officer: President an..
 Common Stock 10,890 $1.69 $18,415
Sale
PETERS RICHARD director, officer: President an..
 Common Stock 4,584 $1.85 $8,476
Sale
EPSTEIN MARIE officer: Principal Accounting O..
 Common Stock 1,806 $1.2 $2,158
Sale
SMITH DEVIN WHITTEMORE officer: SVP and General Counsel
 Common Stock 2,923 $1.2 $3,493
Sale
PETERS RICHARD director, officer: President an..
 Common Stock 10,206 $1.2 $12,196
Sale
WYZGA MICHAEL D officer: Sr. VP & Chief Financi..
 Common Stock 2,887 $1.2 $3,450
Sale
PETERS RICHARD director, officer: President an..
 Common Stock 10,715 $1.85 $19,780
YMTX insider trading transactions

Yumanity Therapeutics
Latest News

Monday, 5 December 2022
InvestorPlace
InvestorPlace
Monday, 6 June 2022
PennyStocks
InvestorPlace
Benzinga
Thursday, 12 May 2022
Zacks Investment Research
Tuesday, 4 January 2022
GlobeNewsWire
Tuesday, 16 November 2021
GlobeNewsWire
Wednesday, 10 November 2021
Benzinga
Thursday, 14 October 2021
GlobeNewsWire

Frequently Asked Questions (FAQ)

  • What's the price of Yumanity Therapeutics stock today?

    One share of Yumanity Therapeutics stock can currently be purchased for approximately $1.89.

  • When is Yumanity Therapeutics's next earnings date?

    Unfortunately, Yumanity Therapeutics's (YMTX) next earnings date is currently unknown.

  • Does Yumanity Therapeutics pay dividends?

    No, Yumanity Therapeutics does not pay dividends.

  • How much money does Yumanity Therapeutics make?

    Yumanity Therapeutics has a market capitalization of 15.72M.

  • What is Yumanity Therapeutics's stock symbol?

    Yumanity Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "YMTX".

  • What is Yumanity Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Yumanity Therapeutics?

    Shares of Yumanity Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Yumanity Therapeutics have?

    As Dec 2024, Yumanity Therapeutics employs 40 workers.

  • When Yumanity Therapeutics went public?

    Yumanity Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 11 Feb 2016.

  • What is Yumanity Therapeutics's official website?

    The official website for Yumanity Therapeutics is yumanity.com.

  • Where are Yumanity Therapeutics's headquarters?

    Yumanity Therapeutics is headquartered at 40 Guest Street, Boston, MA.

  • How can i contact Yumanity Therapeutics?

    Yumanity Therapeutics's mailing address is 40 Guest Street, Boston, MA and company can be reached via phone at +61 74095300.

Yumanity Therapeutics company profile:

Yumanity Therapeutics, Inc.

yumanity.com
Exchange:

NASDAQ

Full time employees:

40

Industry:

Biotechnology

Sector:

Healthcare

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

+61 74095300
40 Guest Street
Boston, MA 02135

CIK: 0001445283
ISIN: US98872L1026
CUSIP: 98872L102